Form 8-K

8-K — ABBOTT LABORATORIES

Accession: 0001628280-26-066601

Filed: 2026-10-21

Period: 2026-10-21

CIK: 0000001800

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — abt-20261021.htm (Primary)

EX-99.1 (abt-2026q3xexhibitx991.htm)

GRAPHIC (image.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: abt-20261021.htm · Sequence: 1

abt-20261021

0000001800FALSENew York Stock ExchangeCHX00000018002026-10-212026-10-210000001800exch:XNYS2026-10-212026-10-210000001800exch:XCHI2026-10-212026-10-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

_______________________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

October 21, 2026

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

_______________________________________________________

Illinois 1-2189 36-0698440

(State or other Jurisdiction

of Incorporation) (Commission File Number) (IRS Employer

Identification  No.)

_______________________________________________________

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class

Trading

Symbol(s)

Name of Each Exchange

on Which Registered

Common Shares, Without Par Value ABT

New York Stock Exchange

NYSE Texas

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition

On October 21, 2026, Abbott Laboratories announced its results of operations for the third quarter 2026.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal settlements, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

Item 9.01 Financial Statements and Exhibits

Exhibit No. Exhibit

99.1

Press Release dated October 21, 2026 (furnished pursuant to Item 2.02).

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBOTT LABORATORIES

Date: October 21, 2026 By: /s/ Philip P. Boudreau

Philip P. Boudreau

Executive Vice President, Finance and Chief Financial Officer

EX-99.1

Filename: abt-2026q3xexhibitx991.htm · Sequence: 2

Document

Exhibit 99.1

News Release

Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance

–Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent

–Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42

–Expands portfolio with key new product approvals

ABBOTT PARK, Ill., Oct. 21, 2026 — Abbott today announced financial results for the third quarter ended Sept. 30, 2026.

•Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis.

•Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items.

•Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent1.

•Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55.

•In August, Abbott announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.

•In August, Abbott announced that the company received CE Mark for its Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).

•In August, Abbott announced the launch of Similac® 360 Total Care® Made With Whole Milk — the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States.

•In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients battling atrial fibrillation.

•In September, Abbott launched SimpleScreen™ CRC, an FDA-approved, blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease.

"Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," said Robert B. Ford, chairman and chief executive officer, Abbott. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead."

Page 1 of 21

THIRD-QUARTER BUSINESS OVERVIEW

Comparable sales growth:

Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices

U.S. 5,504 958 1,853 — 2,687

International 7,509 1,304 1,452 1,614 3,139

Total reported 13,013 2,262 3,305 1,614 5,826

% Change vs. 3Q25

U.S. 28.0 7.9 109.2 n/a 6.6

International 6.2 3.1 6.2 6.8 7.2

Total reported 14.5 5.1 46.7 6.8 6.9

Total reported excl. foreign exchange impact 14.8 4.9 46.6 8.4 7.4

Comparable sales growth 7.0 4.9 6.4 8.4 7.8

U.S. 7.9 7.9 8.4 n/a 7.6

International 6.4 2.8 4.0 8.4 8.0

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices

U.S. 14,994 2,673 4,418 — 7,890

International 21,776 3,750 4,159 4,539 9,328

Total reported 36,770 6,423 8,577 4,539 17,218

% Change vs. 9M25

U.S. 17.7 (4.5) 72.0 n/a 7.1

International 8.2 1.1 6.3 9.3 11.7

Total reported 11.9 (1.3) 32.4 9.3 9.6

Total reported excl. foreign exchange impact 10.5 (2.1) 30.8 8.7 7.8

Comparable sales growth 5.2 (2.1) 3.8 8.7 8.2

U.S. 4.7 (4.5) 4.9 n/a 8.1

International 5.7 (0.3) 2.4 8.7 8.3

Refer to pages 16 and 17 for a reconciliation of comparable sales growth.

Page 2 of 21

Nutrition

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total Pediatric Adult

U.S. 958 577 381

International 1,304 486 818

Total reported 2,262 1,063 1,199

% Change vs. 3Q25

U.S. 7.9 11.0 3.5

International 3.1 6.4 1.3

Total reported 5.1 8.8 2.0

Total reported excl. foreign exchange impact 4.9 8.7 1.8

Comparable sales growth 4.9 8.7 1.8

U.S. 7.9 11.0 3.5

International 2.8 6.0 1.0

Worldwide Nutrition sales increased 5.1 percent on a reported basis and 4.9 percent on a comparable basis in the third quarter.

Worldwide Nutrition results were driven by broad-based growth across the portfolio, including sales growth of nearly 9.0 percent in Worldwide Pediatric.

On a sequential basis, Worldwide Nutrition sales increased $118 million compared to the second quarter of 2026.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total Pediatric Adult

U.S. 2,673 1,613 1,060

International 3,750 1,428 2,322

Total reported 6,423 3,041 3,382

% Change vs. 9M25

U.S. (4.5) (4.8) (4.0)

International 1.1 3.7 (0.5)

Total reported (1.3) (1.0) (1.6)

Total reported excl. foreign exchange impact (2.1) (1.6) (2.6)

Comparable sales growth (2.1) (1.6) (2.6)

U.S. (4.5) (4.8) (4.0)

International (0.3) 2.4 (2.0)

Page 3 of 21

Diagnostics*

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total Core Laboratory Cancer Diagnostics Rapid/Molecular Diagnostics

U.S. 1,853 389 938 526

International 1,452 1,049 30 373

Total reported 3,305 1,438 968 899

% Change vs. 3Q25

U.S. 109.2 6.3 n/a 1.1

International 6.2 5.1 n/a 1.0

Total reported 46.7 5.4 n/a 1.1

Total reported excl. foreign exchange impact 46.6 5.4 n/a 0.9

Comparable sales growth 6.4 5.4 13.8 0.9

U.S. 8.4 6.3 13.9 1.1

International 4.0 5.1 12.1 0.7

Worldwide Diagnostics sales increased 46.7 percent on a reported basis and 6.4 percent on a comparable basis in the third quarter.

Worldwide Core Laboratory Diagnostics results were driven by balanced growth across major geographic regions including the U.S., Europe, Japan, and Latin America.

Cancer Diagnostics results were driven by growth of Cologuard® and also reflect contributions to growth from the precision oncology and international businesses.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total Core Laboratory Cancer Diagnostics Rapid/Molecular Diagnostics

U.S. 4,418 1,113 1,921 1,384

International 4,159 3,015 62 1,082

Total reported 8,577 4,128 1,983 2,466

% Change vs. 9M25

U.S. 72.0 6.1 n/a (8.9)

International 6.3 5.8 n/a 1.9

Total reported 32.4 5.9 n/a (4.5)

Total reported excl. foreign exchange impact 30.8 4.0 n/a (5.4)

Comparable sales growth 3.8 4.0 13.5 (5.4)

U.S. 4.9 6.1 13.5 (8.9)

International 2.4 3.2 15.0 (0.4)

*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.

Refer to pages 16 and 17 for a reconciliation of comparable sales growth.

Page 4 of 21

Established Pharmaceuticals

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total Key Emerging Markets Other

U.S. — — —

International 1,614 1,195 419

Total reported 1,614 1,195 419

% Change vs. 3Q25

U.S. n/a n/a n/a

International 6.8 9.0 1.1

Total reported 6.8 9.0 1.1

Total reported excl. foreign exchange impact 8.4 10.9 1.6

Comparable sales growth 8.4 10.9 1.6

U.S. n/a n/a n/a

International 8.4 10.9 1.6

Established Pharmaceuticals sales increased 6.8 percent on a reported basis and 8.4 percent on a comparable basis in the third quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.0 percent on a reported basis and 10.9 percent on a comparable basis, led by double-digit growth in India and several markets across the Latin America and Asia Pacific regions.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total Key Emerging Markets Other

U.S. — — —

International 4,539 3,448 1,091

Total reported 4,539 3,448 1,091

% Change vs. 9M25

U.S. n/a n/a n/a

International 9.3 10.5 5.6

Total reported 9.3 10.5 5.6

Total reported excl. foreign exchange impact 8.7 10.4 3.6

Comparable sales growth 8.7 10.4 3.6

U.S. n/a n/a n/a

International 8.7 10.4 3.6

Page 5 of 21

Medical Devices

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total Rhythm Management Electro-physiology* Heart Failure Vascular Structural Heart* Neuro-modulation Diabetes Care

U.S. 2,687 380 429 303 290 228 185 872

International 3,139 372 444 84 496 364 66 1,313

Total reported 5,826 752 873 387 786 592 251 2,185

% Change vs. 3Q25

U.S. 6.6 9.0 18.1 8.4 3.4 (11.1) (5.6) 9.4

International 7.2 10.4 12.2 (2.7) 6.7 12.2 13.6 4.2

Total reported 6.9 9.7 15.0 5.8 5.4 1.9 (1.2) 6.2

Total reported excl. foreign exchange impact 7.4 10.0 15.5 6.0 5.7 2.6 (1.1) 6.7

Comparable sales growth 7.8 10.0 15.5 6.0 5.7 6.9 (1.1) 6.7

U.S. 7.6 9.0 18.1 8.4 3.4 (2.3) (5.6) 9.4

International 8.0 11.0 13.1 (1.6) 7.1 13.5 13.9 4.9

Worldwide Medical Devices sales increased 6.9 percent on a reported basis and 7.8 percent on a comparable basis in the third quarter.

Sales growth in the quarter was led by double-digit growth in Electrophysiology and Rhythm Management.

In Diabetes Care, sales of continuous glucose monitors grew 7.3 percent on a reported basis and 7.7 percent on a comparable basis.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total Rhythm Management Electro-physiology* Heart Failure Vascular Structural Heart* Neuro-modulation Diabetes Care

U.S. 7,890 1,096 1,227 908 875 677 551 2,556

International 9,328 1,083 1,295 269 1,491 1,090 203 3,897

Total reported 17,218 2,179 2,522 1,177 2,366 1,767 754 6,453

% Change vs. 9M25

U.S. 7.1 10.4 16.0 10.2 5.2 (10.2) (2.4) 9.3

International 11.7 13.9 14.5 7.9 8.0 16.1 18.1 10.5

Total reported 9.6 12.1 15.2 9.7 7.0 4.4 2.4 10.0

Total reported excl. foreign exchange impact 7.8 10.6 13.8 8.9 5.2 2.6 1.3 7.7

Comparable sales growth 8.2 10.6 13.8 8.9 5.2 6.5 1.3 7.7

U.S. 8.1 10.4 16.0 10.2 5.2 (2.3) (2.4) 9.3

International 8.3 10.8 11.9 4.6 5.2 12.8 13.5 6.6

*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 and $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.

Refer to pages 16 and 17 for a reconciliation of comparable sales growth.

Page 6 of 21

Abbott's Financial Guidance

Abbott projects full-year 2026 comparable sales growth to be approximately 6.0%1.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to $5.55.

Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

Abbott Declares 411th Consecutive Quarterly Dividend

On Sept. 17, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

Page 7 of 21

— Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Abbott Financial:

Michael Comilla, 224-668-1872

Tamika McLoughlin, 224-399-5082

Randy Blakley, 224-668-0036

Abbott Media:

Karen Twigg May, 224-668-2681

Kate Dyer, 224-668-9965

1.In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott’s Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million.

Page 8 of 21

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Third Quarter Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

3Q26 3Q25 % Change

Net Sales $13,013 $11,369 14.5

Cost of products sold, excluding amortization expense 5,628 5,075 10.9

Amortization of intangible assets 841 420 n/m

Research and development 920 766 20.1

Selling, general, and administrative 4,266 3,051 39.8

Total Operating Cost and Expenses 11,655 9,312 25.2

Operating Earnings 1,358 2,057 (34.0)

Interest expense, net 297 44 n/m

Net foreign exchange (gain) loss (6) (17) n/m

Other (income) expense, net (164) (150) 9.4

Earnings before taxes 1,231 2,180 (43.5)

Taxes on Earnings 311 536 (42.0) 1)

Net Earnings $920 $1,644 (44.1)

Net Earnings excluding Specified Items, as described below $2,477 $2,278 8.7 2)

Diluted Earnings per Common Share $0.53 $0.94 (43.6)

Diluted Earnings per Common Share, excluding Specified Items, as described below $1.42 $1.30 9.2 2)

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,738 1,749

NOTES:

See tables on page 13 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

Page 9 of 21

1)2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.557 billion, or $0.89 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $634 million, or $0.36 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.

Page 10 of 21

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Nine Months Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

9M26 9M25 % Change

Net Sales $36,770 $32,869 11.9

Cost of products sold, excluding amortization expense 15,843 14,397 10.0

Amortization of intangible assets 1,921 1,260 52.4

Research and development 2,579 2,207 16.9

Selling, general, and administrative 12,031 9,203 30.7

Total Operating Cost and Expenses 32,374 27,067 19.6

Operating Earnings 4,396 5,802 (24.2)

Interest expense, net 664 143 n/m

Net foreign exchange (gain) loss (15) (35) n/m

Other (income) expense, net (457) (414) 10.2

Earnings before taxes 4,204 6,108 (31.2)

Taxes on earnings 1,279 1,360 (6.0) 1)

Net Earnings $2,925 $4,748 (38.4)

Net Earnings excluding Specified Items, as described below $6,789 $6,410 5.9 2)

Diluted Earnings per Common Share $1.67 $2.70 (38.1)

Diluted Earnings per Common Share,

excluding Specified Items, as described below

$3.88 $3.65 6.3 2)

Average Number of Common Shares Outstanding

Plus Dilutive Common Stock Options

1,743 1,749

NOTES:

See tables on page 14 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

Page 11 of 21

1)2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $3.864 billion, or $2.21 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.662 billion, or $0.95 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

Page 12 of 21

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Third Quarter Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

3Q26

As Reported (GAAP) Specified Items As Adjusted

Intangible Amortization

$ 841 $ (841) $ —

Gross Margin

6,544 904 7,448

R&D

920 (28) 892

SG&A

4,266 (761) 3,505

Other (income) expense, net

(164) 4 (160)

Earnings before taxes

1,231 1,689 2,920

Taxes on Earnings

311 132 443

Net Earnings

920 1,557 2,477

Diluted Earnings per Share

$ 0.53 $ 0.89 $ 1.42

Specified items reflect intangible amortization expense of $841 million, legal settlements of approximately $670 million and other net expenses of $178 million associated with acquisitions, restructuring actions, and other net expenses. See page 18 for additional details regarding specified items.

3Q25

As Reported (GAAP) Specified Items As Adjusted

Intangible Amortization

$ 420 $ (420) $ —

Gross Margin

5,874 470 6,344

R&D

766 (36) 730

SG&A

3,051 (47) 3,004

Other (income) expense, net

(150) 5 (145)

Earnings before taxes

2,180 548 2,728

Taxes on Earnings

536 (86) 450

Net Earnings

1,644 634 2,278

Diluted Earnings per Share

$ 0.94 $ 0.36 $ 1.30

Specified items reflect intangible amortization expense of $420 million and other net expenses of $128 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See page 19 for additional details regarding specified items.

Page 13 of 21

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Nine Months Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

9M26

Reported (GAAP) Specified Items As

Adjusted

Intangible Amortization

$ 1,921 $ (1,921) $ —

Gross Margin

19,006 2,033 21,039

R&D

2,579 (77) 2,502

SG&A

12,031 (1,662) 10,369

Other (income) expense, net

(457) (30) (487)

Earnings before taxes

4,204 3,802 8,006

Taxes on Earnings

1,279 (62) 1,217

Net Earnings

2,925 3,864 6,789

Diluted Earnings per Share

$ 1.67 $ 2.21 $ 3.88

Specified items reflect intangible amortization expense of $1.921 billion, legal settlements of approximately $1.070 billion and other net expenses of $811 million associated with acquisitions, restructuring actions, and other net expenses. See page 20 for additional details regarding specified items.

9M25

Reported (GAAP) Specified Items As

Adjusted

Intangible Amortization

$ 1,260 $ (1,260) $ —

Gross Margin

17,212 1,396 18,608

R&D

2,207 (83) 2,124

SG&A

9,203 (58) 9,145

Other (income) expense, net

(414) (31) (445)

Earnings before taxes

6,108 1,568 7,676

Taxes on Earnings

1,360 (94) 1,266

Net Earnings

4,748 1,662 6,410

Diluted Earnings per Share

$ 2.70 $ 0.95 $ 3.65

Specified items reflect intangible amortization expense of $1.260 billion and other net expenses of $308 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See page 21 for additional details regarding specified items.

Page 14 of 21

A reconciliation of the third-quarter tax rates for 2026 and 2025 is shown below:

3Q26

($ in millions) Pre-Tax

Income Taxes on

Earnings Tax

Rate

As reported (GAAP) $ 1,231 $ 311 25.3 % 1)

Specified items 1,689 132

Excluding specified items $ 2,920 $ 443 15.2 %

3Q25

($ in millions) Pre-Tax

Income Taxes on

Earnings Tax

Rate

As reported (GAAP) $ 2,180 $ 536 24.6 % 2)

Specified items 548 (86)

Excluding specified items $ 2,728 $ 450 16.5 %

2)2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below:

9M26

($ in millions) Pre-Tax

Income Taxes on

Earnings Tax

Rate

As reported (GAAP) $ 4,204 $ 1,279 30.4 % 3)

Specified items 3,802 (62)

Excluding specified items $ 8,006 $ 1,217 15.2 %

9M25

($ in millions) Pre-Tax

Income Taxes on

Earnings Tax

Rate

As reported (GAAP) $ 6,108 $ 1,360 22.3 % 4)

Specified items 1,568 (94)

Excluding specified items $ 7,676 $ 1,266 16.5 %

3)2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

4)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 15 of 21

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

Third Quarter Ended September 30, 2026 and 2025

($ in millions)

(unaudited)

3Q26 3Q25 % Change vs. 3Q25

Non-GAAP

Abbott Reported Foreign exchange Comparable Revenue Abbott Reported Impact of acquisition (a) Impact

of multi-year agreement (b) Comparable Revenue Reported Comparable

Total Company 13,013 40 13,053 11,369 851 (23) 12,197 14.5 7.0

U.S. 5,504 — 5,504 4,299 824 (23) 5,100 28.0 7.9

Intl 7,509 40 7,549 7,070 27 — 7,097 6.2 6.4

Total Diagnostics 3,305 (2) 3,303 2,253 851 — 3,104 46.7 6.4

U.S. 1,853 — 1,853 886 824 — 1,710 109.2 8.4

Intl 1,452 (2) 1,450 1,367 27 — 1,394 6.2 4.0

Total Cancer Diagnostics 968 — 968 — 851 — 851 n/a 13.8

U.S. 938 — 938 — 824 — 824 n/a 13.9

Intl 30 — 30 — 27 — 27 n/a 12.1

Total Medical Devices 5,826 22 5,848 5,448 — (23) 5,425 6.9 7.8

U.S. 2,687 — 2,687 2,521 — (23) 2,498 6.6 7.6

Intl 3,139 22 3,161 2,927 — — 2,927 7.2 8.0

Total Structural Heart* 592 4 596 580 — (23) 557 1.9 6.9

U.S. 228 — 228 256 — (23) 233 (11.1) (2.3)

Intl 364 4 368 324 — — 324 12.2 13.5

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 were moved from Structural Heart to Electrophysiology.

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

b) Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Page 16 of 21

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

Nine Months Ended September 30, 2026 and 2025

($ in millions)

(unaudited)

9M26 9M25 % Change vs. 9M25

Non-GAAP

Abbott Reported Impact of acquisition (a) Impact

of multi-year agreement (b) Foreign exchange Comparable Revenue Abbott Reported Impact of acquisition (a) Impact

of multi-year agreement (b) Comparable Revenue Reported Comparable

Total Company 36,770 706 (8) (460) 37,008 32,869 2,369 (69) 35,169 11.9 5.2

U.S. 14,994 681 (8) — 15,667 12,743 2,294 (69) 14,968 17.7 4.7

Intl 21,776 25 — (460) 21,341 20,126 75 — 20,201 8.2 5.7

Total Diagnostics 8,577 706 — (100) 9,183 6,480 2,369 — 8,849 32.4 3.8

U.S. 4,418 681 — — 5,099 2,568 2,294 — 4,862 72.0 4.9

Intl 4,159 25 — (100) 4,084 3,912 75 — 3,987 6.3 2.4

Total Cancer Diagnostics 1,983 706 — (1) 2,688 — 2,369 — 2,369 n/a 13.5

U.S. 1,921 681 — — 2,602 — 2,294 — 2,294 n/a 13.5

Intl 62 25 — (1) 86 — 75 — 75 n/a 15.0

Total Medical Devices 17,218 — (8) (284) 16,926 15,712 — (69) 15,643 9.6 8.2

U.S. 7,890 — (8) — 7,882 7,363 — (69) 7,294 7.1 8.1

Intl 9,328 — — (284) 9,044 8,349 — — 8,349 11.7 8.3

Total Structural Heart* 1,767 — (8) (31) 1,728 1,692 — (69) 1,623 4.4 6.5

U.S. 677 — (8) — 669 753 — (69) 684 (10.2) (2.3)

Intl 1,090 — — (31) 1,059 939 — — 939 16.1 12.8

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

Page 17 of 21

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds

Gross Margin $ 10 $ 29 $ 841 $ 24 $ 904

R&D (7) (5) — (16) (28)

SG&A (47) (20) — (694) (761)

Other (income) expense, net (8) (1) — 13 4

Earnings before taxes $ 72 $ 55 $ 841 $ 721 1,689

Taxes on Earnings (d) 132

Net Earnings $ 1,557

Diluted Earnings per Share $ 0.89

The table above provides additional details regarding the specified items described on page 13.

a)Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.

c)Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants, as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 18 of 21

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds

Gross Margin $ — $ 44 $ 420 $ 6 $ 470

R&D — (19) — (17) (36)

SG&A (9) (43) — 5 (47)

Other (income) expense, net 7 — — (2) 5

Earnings before taxes $ 2 $ 106 $ 420 $ 20 548

Taxes on Earnings (d) (86)

Net Earnings $ 634

Diluted Earnings per Share $ 0.36

The table above provides additional details regarding the specified items described on page 13.

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)Reflects the net tax benefit associated with the specified items. Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 19 of 21

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds

Gross Margin $ 44 $ 40 $ 1,921 $ 28 $ 2,033

R&D (18) (15) — (44) (77)

SG&A (533) (54) — (1,075) (1,662)

Other (income) expense, net (9) (4) — (17) (30)

Earnings before taxes $ 604 $ 113 $ 1,921 $ 1,164 3,802

Taxes on Earnings (d) (62)

Net Earnings $ 3,864

Diluted Earnings per Share $ 2.21

The table above provides additional details regarding the specified items described on page 14.

a)Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.

b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.

c)Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the NEC claims asserted on behalf of approximately 2,000 additional infants; approximately $400 million, including attorneys' fees and accrued interest, related to an agreement to resolve the United States Department of Justice (DOJ) investigations and the civil qui tam lawsuit brought by certain relators and joined by the DOJ and Attorneys General of several states; as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 20 of 21

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds

Gross Margin $ 1 $ 125 $ 1,260 $ 10 $ 1,396

R&D (1) (42) — (40) (83)

SG&A (15) (49) — 6 (58)

Other (income) expense, net (18) — — (13) (31)

Earnings before taxes $ 35 $ 216 $ 1,260 $ 57 1,568

Taxes on Earnings (d) (94)

Net Earnings $ 1,662

Diluted Earnings per Share $ 0.95

The table above provides additional details regarding the specified items described on page 14.

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.

d)Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 21 of 21

GRAPHIC

Filename: image.jpg · Sequence: 7

Binary file (43759 bytes)

Download image.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.3

Cover

Oct. 21, 2026

Document Information [Line Items]

Document Type

8-K

Document Period End Date

Oct. 21, 2026

Entity Registrant Name

ABBOTT LABORATORIES

Entity Incorporation, State or Country Code

Entity File Number

1-2189

Entity Tax Identification Number

36-0698440

Entity Address, Address Line One

100 Abbott Park Road

Entity Address, City or Town

Abbott Park

Entity Address, State or Province

Entity Address, Postal Zip Code

60064-6400

City Area Code

224

Local Phone Number

667-6100

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Entity Central Index Key

0000001800

Amendment Flag

false

NYSE CHICAGO, INC.

Document Information [Line Items]

Title of 12(b) Security

Common Shares, Without Par Value

Trading Symbol

ABT

Security Exchange Name

CHX

NEW YORK STOCK EXCHANGE, INC.

Document Information [Line Items]

Title of 12(b) Security

Common Shares, Without Par Value

Trading Symbol

ABT

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

dei_EntityListingsExchangeAxis=exch_XCHI

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

dei_EntityListingsExchangeAxis=exch_XNYS

Namespace Prefix:

Data Type:

Balance Type:

Period Type: